profit from every SEK 100 of sales.
SEK 0SEK 100
Swedish Orphan Biovitrum
SEK 474.20-2.63% today
+45.4% in 1 year
1-year low SEK 324.201-year high SEK 498.20
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay SEK 34.27 for every SEK 1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Swedish Orphan Biovitrum sold, what it kept, and what it did with the cash.
Sales went from $18.8 billion in 2022 to $28.2 billion in 2025, with $478 million of profit last year.
SalesProfit
Swedish Orphan Biovitrum vs. similar companies
Swedish Orphan Biovitrum grows the fastest of these 5 and is priced in the middle for its profits.
| Company | Profit from SEK 100 of sales | Sales growth a year | Price per SEK 1 of profit |
|---|---|---|---|
| Swedish Orphan Biovitrum | 34.3× · Expensive | ||
 Merck KGaA | 24.9× · Fair price | ||
 Takeda Pharmaceutical | 102.5× · Very expensive | ||
 Galderma Group | 86.9× · Very expensive | ||
 Teva Pharmaceutical Industries | 36.8× · Expensive |
AI analysis
An AI analyst reads Swedish Orphan Biovitrum's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 18,790 | 22,123 | 26,027 | 28,238 | |
| 14,014 | 17,128 | 20,242 | 21,986 | |
| 3,845 | 4,180 | 5,617 | 922 | |
| 6,051 | 7,265 | 9,325 | 10,932 | |
| 2,638 | 2,409 | 3,885 | 478 | |
| 8.44 | 7.39 | 11.24 | 1.37 | |
| 74.6% | 77.4% | 77.8% | 77.9% | |
| 20.5% | 18.9% | 21.6% | 3.3% | |
| 14.0% | 10.9% | 14.9% | 1.7% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 52,496 | 74,027 | 75,444 | 67,434 |
| Cash | 1,361 | 904 | 1,140 | 1,041 |
| Total debt | 9,101 | 20,486 | 16,735 | 11,495 |
| Total liabilities | 25,971 | 40,160 | 35,149 | 29,711 |
| 26,525 | 33,867 | 40,286 | 37,717 | |
| 312 | 326 | 346 | 348 | |
| 8.4% | 5.9% | 7.9% | 1.3% | |
| 9.9% | 7.1% | 9.6% | 1.3% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 4,576 | 4,470 | 7,388 | 8,565 | |
| 1,477 | 4,943 | 3,005 | 3,153 | |
| 3,099 | -473 | 4,383 | 5,412 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| – | – | 218 | 250 |
Valuation
- 34.3×
- –
- –
- 4.0×
- 0.6×
- 3.0×
- 2.5×
- 33.0%
- 2.9%
- –
Profitability
- 77.9%
- 3.3%
- 1.7%
- –
- 1.3%
- 5.9%
- –
- –
- –
- –
Growth
- +14.5%
- −45.5%
- –
- –
- +3.6%
Financial health
- 1.0×
- 0.30
- –
- 1.0×
- 0.90
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 34%of 963
Bottom 30%of 894
Bottom 38%of 632
Top 38%of 908
Top 1%of 991
News
BAE Systems advances U.S., Swedish, Australian defense programsSeeking Alpha · Aug 26, 2026The newest story we have is from Aug 26, 2026.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
40No pass
Benjamin Graham
37No pass
Philip Fisher
36No pass
Peter Lynch
31No pass
Joel Greenblatt
4No pass
Charlie Munger
24No pass
Terry Smith
30No pass
Questions about Swedish Orphan Biovitrum
Is Swedish Orphan Biovitrum a good stock to buy?
A business with weak numbers, but the price is high. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Swedish Orphan Biovitrum AI analysis
What does Swedish Orphan Biovitrum do?
Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It is in Drug Manufacturers - Specialty & Generic, based in Stockholm, Sweden, with 1,969 employees.
Is Swedish Orphan Biovitrum stock halal?
Yes. Swedish Orphan Biovitrum passes our halal screen: its business is permitted and its debt is 7% of its market value, under the 30% limit. How we check
How has Swedish Orphan Biovitrum stock done over the past year?
Up 45.4% over the past twelve months, to SEK 474.20. It traded between SEK 324.20 and SEK 498.20 and is 4.8% below its high.
Who are Swedish Orphan Biovitrum's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with Swedish Orphan Biovitrum's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.